Neuro

Question 1

Ropinirole, Pramipexole

Answer 1

DA agonists

Question 2

Apomorphine, Rotigotine

Answer 2

DA agonists

Question 3

Bromocriptine

Answer 3

Ergot DA agonist

Question 4

Entacapone, Tocapone

Answer 4

COMT inhibitors (Tolcapone prevents central and peripheral DA breakdown)

Question 5

Amantadine

Answer 5

NMDA antagonist

Question 6

Rasagiline, Safinamide, Selegiline

Answer 6

MAO-B inhibitors (Parkinsons)

Question 7

Benztropine, Trihexyphenidyl, Biperiden

Answer 7

Anticholinergic drugs for Parkinson’s

Question 8

Aducanumab

Answer 8

Aβ monoclonal antibody for Alzheimer disease

Question 9

Rivastigmine, Galantamine, Donepezil

Answer 9

AChEIs (first-line treatment for Alzheimer)

Question 10

Carbamazepine

Answer 10

Blocks Na+ channels in partial seizures

Question 11

Ethosuximide

Answer 11

Blocks T-type Ca2+ channels for absence seizures

Question 12

Lamotrigine

Answer 12

Blocks voltage-gated Ca2+ channels and is a GABA analog

Question 13

Levetiracetam

Answer 13

SV2A receptor blocker, may modulate GABA and glutamate release, inhibits voltage-gated Ca2+ channels

Question 14

Phenobarbital

Answer 14

Increases GABA action

Question 15

Phenytoin, fosphenytoin

Answer 15

Blocks Na+ channels

Question 16

Topiramate

Answer 16

Blocks Na+ channels and increases GABA action

Question 17

Valproate

Answer 17

Increases Na+ channel inactivation and increases GABA concentration

Question 18

Vigabatrin

Answer 18

Increases GABA by inhibiting GABA transaminase

Question 19

Zolpidem, Zaleplon, Eszopiclone

Answer 19

Nonbenzodiazepine hypnotics

Question 20

Suvorexant

Answer 20

Orexin (hypocretin) receptor antagonist

Question 21

Ramelteon

Answer 21

Melatonin receptor agonist: binds MT1 and MT2 in suprachiasmatic nucleus

Question 22

Triptans MOA

Answer 22

5-HT agonists, inhibits trigeminal nerve activation, prevents vasoactive peptide release and induces vasoconstriction

Question 23

Amantadine

Answer 23

Increases DA release and decreases DA reuptake; mainly used to reduce levodopa-induced dyskinesias

Question 24

Riluzole (ALS)

Answer 24

Decreases neuron glutamate excitotoxicity

Question 25

Tetrabenazine (Huntington's disease)

Answer 25

Inhibits VMAT, leading to decreased DA vesicle packaging and release

Question 26

Midazolam (anesthetic)

Answer 26

Facilitates GABA

Question 27

Propofol (anesthetic)

Answer 27

Potentiates GABA

Question 28

Thiopental (anesthetic)

Answer 28

Facilitates GABA (barbiturate)

Question 29

Procaine, tetracaine, benzocaine, chloroprocaine

Answer 29

Ester anesthetics

Question 30

Lidocaine, mepivacaine, bupivacaine, ropivacine, prilocaine

Answer 30

Amide anesthetics

Question 31

Local anesthetics

Answer 31

Block neurotransmission via binding to voltage-gasted Na+ channels on inner portion of channel

Question 32

Succinylcholine

Answer 32

Strong Nm nicotinic receptor agonist

Question 33

Atracurium, cisatracurium, pancuronium, rocuronium, tubicurarine

Answer 33

Competitive Nm nicotinic receptor antagonists

Question 34

Baclofen

Answer 34

GABAb receptor agonist in spinal cord

Question 35

Dantrolene

Answer 35

Prevents Ca2+ release from SR of skeletal muscle by inhibiting RYR

Question 36

Tramadol

Answer 36

Weak opioid agonists and inhibits NE and 5-HT reuptake

Question 37

Pentazocine

Answer 37

κ-opioid agonists and weak μ-antagonists or partial agonist

Question 38

Butorphanol

Answer 38

κ-opioid agonists and weak μ-partial agonist

Question 39

Capsaicin

Answer 39

Desensitization of nociceptive fibers by decreasing substance P release